Ser68

Site Information
PSDLsPEsPMLssPP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454282

In vivo Characterization
Methods used to characterize site in vivo:	[32P] ATP in vitro ( 5 ) , mass spectrometry ( 1 , 2 , 3 , 6 , 7 ) , mutation of modification site ( 5 )
Disease tissue studied:	breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 6 ) , acute myelogenous leukemia ( 6 )
Relevant cell line - cell type - tissue:	breast ( 1 , 2 ) , Jurkat (T lymphocyte) ( 3 , 7 ) , KG-1 (myeloid) ( 6 )

Upstream Regulation
Kinases, in vitro:	CDK5 (human) ( 5 ) , ERK2 (human) ( 5 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
4	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
5	Devaux S, et al. (2012) Specific Serine-Proline Phosphorylation and Glycogen Synthase Kinase 3β-directed Subcellular Targeting of Stathmin 3/Sclip in Neurons. J Biol Chem 287, 22341-53 22577147 Curated Info
6	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
7	Moritz A (2009) CST Curation Set: 8213; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info